

Index

- Acinar region, pathology 8, 10
Acute chest syndrome 264–6
 diagnosis 266–7
 multiorgan failure 266–8
 treatment 267–8
Acute lung injury 12–14
Acute lupus pneumonitis 341
Adenosine, pulmonary toxicity 426
Adult respiratory distress syndrome 12–14, 245–61
 bronchoalveolar lavage 56
 diagnostic evaluation 251
 normal fluid balance 245–6
 prognosis and outcome 257
 treatment 252–6
 mechanical ventilation 253–6
 non-ventilator techniques 252–3
 supportive care 252, 2526
 see also Pulmonary edema
Airway hyperresponsiveness 71
Airway resistance 75
Alkylating agents, pulmonary toxicity 28, 407, 411–12
 busulfan 411
 chlorambucil 411
 cyclophosphamide 411
 ifosfamide 412
 melphalan 411
Allergic alveolitis *see* Extrinsic allergic alveolitis
Allergic bronchopulmonary aspergillosis 191, 446
 and bronchiectasis 204
Allergic bronchopulmonary mycosis *see* Allergic
 bronchopulmonary aspergillosis
Allergic granulomatosis of Churg-Strauss *see* Churg-Strauss
 syndrome
Allergy testing 188
Alpha₁-antitrypsin deficiency, and COPD 198–9
Alveolar-arterial oxygen pressure difference 73
Alveolar-capillary block syndrome 73
Alveolar hemorrhage
 bronchoalveolar lavage 56
 systemic lupus erythematosus 341–2
Alveolar hyperventilation 406
Alveolar proteinosis 24–5, 452–5
 in children 494, 495
 clinical presentation 452–3
 laboratory testing 454
 physiologic testing 453
 radiographic appearance 453, 454
 treatment and outcome 454–5
Amiodarone, pulmonary toxicity 28, 422–5
Ammonia, pulmonary toxicity 161
 clinical symptoms 163–4
 exposed population 163
 mechanism of lung injury 163
 radiological findings 164
Amyloidosis 295–7
 clinical presentation 296
 diagnosis and treatment 297
 diffuse septal 26
 pathology 25–6
 pulmonary function testing 297
 radiographic findings 296–7
Angioimmunoblastic lymphadenopathy 280
Angiotensin-converting enzyme inhibitors, pulmonary toxicity
 426
Anthrax 129–30
Antibiotics *see* Antimicrobial agents
Anti-inflammatory agents, pulmonary toxicity 415–19
 non-steroidal anti-inflammatory drugs 416–17
 gold 419
 methotrexate 417
 penicillamine 417–19
 salicylates 416
Antimalarial drugs, pulmonary toxicity 421
Antimetabolites, pulmonary toxicity 407, 412–13
 azathioprine 413
 cytosine arabinoside 412–13
 methotrexate 412
Antimicrobial agents
 chronic obstructive pulmonary disease 200
 pulmonary toxicity 419–21
 hypersensitivity lung disease 420
 isoniazid 421
 minocycline 421
 nitrofurantoin 420–1
 see also Cytotoxic antibiotics, pulmonary toxicity
Antineutrophil cytoplasmic antibodies 19, 23
Arterial blood gas analysis 73
Asbestosis 30–1, 152–8
 bronchoalveolar lavage 56
 fibrosing pleurisy 156
 lung cancer 156
 malignant mesothelioma 156

- Asbestosis *continued*
 pleural thickening 155–6
 pulmonary fibrosis 153–5
Ascaris spp. 22
Ascaris lumbricoides 135
 Aspergillosis
 allergic bronchopulmonary 191, 446
 and bronchiectasis 204
 chronic necrotizing pulmonary 138–9
Aspergillus spp. 7, 54, 228, 284
 pneumonia 229, 231–2
 Aspiration 471–3
 chemical pneumonitis 471–2
 and chronic pulmonary fibrosis 496–7
 Aspiration pneumonia 472–3
 Aspirin-induced asthma 191
 Asthma 185–94
 allergic bronchopulmonary aspergillosis 191
 allergy testing 188
 aspirin-induced 191
 clinical presentation 186
 diseases mimicking 187
 in elderly 191
 flexible fiberoptic bronchoscopy 189
 laboratory tests 188
 lung function 188
 occupational 190–1
 pathology 4–5, 185
 physical examination 187–8
 precipitating factors 186–7
 pulmonary function tests 76
 radiological diagnosis 190
 status asthmaticus 191–2
 treatment 192–4
 Auscultation 48
 Auto-immune lung disease 492
 Azathioprine, pulmonary toxicity 407, 413
- Bacillus anthracis* 129–30
 Bacterial infections 229
 leukemia and lymphoma 282–3
 pneumonia 126–30
 Bacterial pneumonia 126–30, 473–4
 Bagassosis 146
 Behçet's syndrome 23
 Berylliosis 31–2
 bronchoalveolar lavage 56
 Beta-adrenergic receptor blocking agents, pulmonary toxicity 426
 Biopsy
 chronic interstitial pneumonitis/fibrosis 326
 Churg-Strauss syndrome 321
 lymphomatoid granulomatosis 318
 open lung 109–10
 percutaneous needle 107
 sarcoidosis 312–13
 surgical 107–8, 119–20
 transbronchial 103–4, 118–19
 Wegener's granulomatosis 315–16
see also Bronchoalveolar lavage; Bronchoscopy
 Bird fancier's disease 145
Blastomyces dermatitidis 54, 135
 Bleomycin, pulmonary toxicity 28, 406–10
 Blue bloaters 195
 Bone marrow transplantation 477–9
 Breathlessness 45–6
 Bronchi, disorders of 3–7
 asthma *see* Asthma
 bronchiectasis *see* Bronchiectasis
 chronic bronchitis 3
 Bronchiectasis 202–10
 ancillary test results 205–6
 clinical diagnosis 205
 pathology 5–7
 pathophysiology 203
 predisposing etiologies 203–5
 allergic bronchopulmonary aspergillosis 204
 central endobronchial obstruction 204
 congenital disorders 203–4
 radiological diagnosis 206–7
 recurrent lower respiratory tract infection 204–5
 cigarette smoking 205
 granulomatous diseases 205
 human immunodeficiency virus 205
 and rheumatoid arthritis 339
 treatment 207–11
 complications 209–10
 controlling bronchial hyperreactivity 210
 controlling infection 210
 managing airway secretions 210
 prevention 210–11
 surgical resection 207–9
 Bronchioalveolar carcinoma 377–401
 clinical presentation 378
 diagnosis 378
 epidemiology 377–8
 lymphangitic carcinomatosis 389–99
 clinical manifestation and definite diagnosis 390–4
 pathology 390
 radiologic diagnosis 394–9
 treatment 399
 pathology 378
 radiological diagnosis 380–8
 cavitation 387–8
 consolidation 381
 differential diagnosis 388–9
 multifocal pattern 381–7
 pathology 380
 solitary pattern 380–1, 382
 treatment and prognosis 379, 380
 Bronchioles 7–8
 Bronchiolitis
 obliterative 339
 pathology 8, 9
 Bronchiolitis obliterans organizing pneumonia 405, 480
 Bronchitis
 chronic
 pathology 3
 pulmonary function tests 76
see also Chronic obstructive pulmonary disease
 Bronchoalveolar lavage 54–60, 104–6, 118–19
 chronic interstitial pneumonitis/fibrosis 326
 clinical uses 55–60
 infectious diseases 60
 interstitial lung disease 57–9
 malignancies 60
 obstructive lung disease 59
 markers 58
 technique 55
see also Biopsy; Bronchoscopy
 Bronchodilators, response to 67–8
 Bronchiolitis obliterans with organizing pneumonia (BOOP) 56
 Bronchoscopy
 fiberoptic 102–3
 asthma 189–90
 chronic obstructive pulmonary disease 197
 cystic fibrosis 214

- flexible fiberoptic *see* Flexible fiberoptic bronchoscopy
- Wegener's granulomatosis 314–15
- Bronchospasm 405
 - mitomycin C-induced 410
- Brugia malayi* 22
- Busulfan, pulmonary toxicity 407, 411
- Byssinosis 146

- Cadmium 168
 - mechanism of lung injury 169
 - radiological findings 169
- Cancer chemotherapy agents, pulmonary toxicity 285–6, 406–15
 - alkylating agents 411–12
 - busulfan 411
 - chlorambucil 411
 - cyclophosphamide 411
 - ifosfamide 412
 - melphalan 411
 - antimetabolites 412–13
 - azathioprine 413
 - cytosine arabinoside 412–13
 - methotrexate 412
 - cytotoxic antibiotics 406–11
 - bleomycin 405–10
 - mitomycin C 410–11
 - interleukin-2 414
 - nitrosoureas 413–14
 - carmustine 413–14
 - chlorozotocin 414
 - fotemustine 414
 - lomustine 414
 - semustine 414
 - paclitaxel and docetaxel 415
 - procarbazine 415
 - retinoic acid 414–15
- Candida* spp. 228, 284
- Candida albicans* 229, 233
- Caplan's syndrome 151
- Carbamazepine, pulmonary toxicity 428
- Cardiac agents, pulmonary toxicity 422–7
 - angiotensin-converting enzyme inhibitors 426
 - antiarrhythmic drugs 422–6
 - adenosine 426
 - amiodarone 422–5
 - flecainide 425
 - mexiletine 426
 - procainamide 425
 - quinidine 425
 - sotalol 426
 - tocainide 425
 - beta-adrenergic receptor blocking agents 426
 - dipyridamole 426–7
 - hydralazine 427
 - protamine 427
- Carmustine, pulmonary toxicity 407, 413–14
- Castleman's disease 281
- Centriacinar emphysema 11
- Chemical pneumonitis 471–2
- Chemotherapy, pulmonary toxicity *see* Cancer chemotherapy agents, pulmonary toxicity
- Chest pain 46
- Chest X-ray 79–85
 - asthma 190
 - bronchiectasis 206
 - bronchioalveolar carcinoma
 - consolidation 381
 - solitary presentation 380
 - chronic obstructive pulmonary disease 197
 - Churg-Strauss syndrome 319–20
 - cystic fibrosis 214–15
 - lymphangitic carcinomatosis 394–5
 - lymphomatoid granulomatosis 317, 318
 - portable 465–7
 - sarcoidosis 305–6
 - Wegener's granulomatosis 314, 315
- Children, interstitial lung disease in 487–98
 - acute conditions
 - Pneumocystis carinii* pneumonia 488–9
 - viral pneumonia 489
 - chronic conditions
 - alveolar proteinosis 494, 495
 - auto-immune lung disease 492
 - chronic pulmonary fibrosis due to recurrent aspiration 496–7
 - fibrosing alveolitis/desquamative interstitial pneumonitis 490–2
 - histiocytosis 492
 - lymphangiomas 494, 496
 - lymphoid interstitial pneumonitis 489–90
 - pulmonary hemosiderosis 493–4, 495
 - sarcoidosis 492–3, 494
- Chlamydia pneumoniae* 469
- Chlamydia psittaci* 128–9
- Chlorambucil, pulmonary toxicity 407, 411
- Chlorine gas, pulmonary toxicity 161
 - clinical symptoms 163
 - exposed population 163
 - mechanism of lung injury 163
 - radiological findings 164
- Chlorzotocin, pulmonary toxicity 407, 414
- Chlorphentermine, pulmonary toxicity 28
- Chronic bronchitis
 - pathology 3
 - pulmonary function tests 76
- Chronic interstitial lung disease 325–7
 - bronchoalveolar lavage 326
 - dermatomyositis 333, 335
 - high resolution thin-section computed tomographic scanning 327
 - lung biopsy in 326
 - mixed connective tissue disease 342–3
 - polymyositis 333, 335
 - progressive systemic sclerosis 328–9
 - radionuclide scanning 326–7
 - rheumatoid arthritis 335–9
 - Sjögren's syndrome 344–7
 - systemic lupus erythematosus 340–1
- Chronic necrotizing pulmonary aspergillosis 138–9
- Chronic obstructive pulmonary disease 3, 194–202
 - alpha1-antitrypsin deficiency 198–9
 - clinical presentation 195
 - and environment 195
 - flexible bronchoscopy 197
 - nuclear imaging 196–7
 - pathophysiology 194–5
 - pulmonary function tests 195–6
 - radiological diagnosis 197–8
 - in smokers 7
 - treatment 199–202
 - antibiotics and mycolytics 200
 - bronchodilators and anticholinergics 200
 - corticosteroids 201
 - education and prevention 199–200
 - lung transplantation 201
 - lung volume reduction surgery 201–2
 - pulmonary rehabilitation 201

- Chronic obstructive pulmonary disease
 treatment *continued*
 supplemental oxygen 201
 theophylline 200
- Churg-Strauss syndrome 21, 319–21, 446–7
 diagnosis 319–21
 biopsy 321
 chest radiograph and computed tomography 319–20
 laboratory findings 320
 treatment 321
- Cigarette smoking 175, 177
 and bronchiectasis 205
see also Smoke inhalation
- Clinical assessment 115–16
- Coagulopathies, and pulmonary hemorrhage 369–70
- Coal pneumoconiosis 29, 148–50
 clinical presentation 149
 management and prevention 150
 radiological features 149–50
- Cobalt 168
 lung disease 32
 mechanism of lung injury 169
 radiological findings 169
- Cocaine, pulmonary toxicity 429
- Coccidioides immitis* 54, 133, 135
- Collagen vascular diseases 325–55
 bronchoalveolar lavage 56
 chronic interstitial pneumonitis/fibrosis 325–7
 overlap syndrome and mixed connective tissue disease 342–3
 polymyositis and dermatomyositis 331–5
 progressive systemic sclerosis 327–31
 chronic interstitial lung disease 328–9
 clinical course and therapy 329–31
 pulmonary hypertension and CREST syndrome 331
 pulmonary involvement 26
 rheumatoid arthritis 335–9
 bronchiectasis 339
 clinical course and therapy 339
 obliterative bronchiolitis 339
- Sjögren's syndrome 343–8
 systemic lupus erythematosus 339–42
 acute alveolar hemorrhage 341–2
 acute lupus pneumonitis 341
 chronic interstitial lung disease 340–1
- Community-acquired bacterial pneumonia 126–30
 intensive care 468–70
- Computed tomography 85–92
 asthma 190
 bronchiectasis 206–7
 bronchioalveolar carcinoma
 consolidation 381
 multifocal type 387
 solitary presentation 380–1, 382
 chest scan 116–18
 chronic interstitial pneumonitis/fibrosis 327
 chronic obstructive pulmonary disease 197–8
 Churg-Strauss syndrome 319–20
 cystic fibrosis 215–16
 intensive care unit 467–8
 lymphangitis carcinomatosa 395–7
 lymphomatoid granulomatosis 317, 318
 sarcoidosis 306–11
 bronchovascular distribution 307
 fibrosis 311
 ground-glass opacities 307–11
 parenchymal nodules 307–11
 pleural/subpleural nodules 307–11
 primary sarcoidosis 307
 Wegener's granulomatosis 314, 315
- Congestive heart failure
 diagnostic evaluation 250–1
 treatment 251–2
see also Pulmonary edema
- Corticosteroids 201
 adult respiratory distress syndrome 256
- Cough 45
Coxiella burnetii 129
 CREST syndrome 331
Cryptococcus neoformans 231
- Cyclophosphamide, pulmonary toxicity 407, 411
- Cystic fibrosis 6–7, 211–17
 clinical presentation 212–13
 flexible fiberoptic bronchoscopy 214
 history and physical examination 213–14
 pathophysiology 211–12
 pulmonary function 214
 radiological findings 214–16
 sweat chloride test 214
 treatment 216–17
- Cystic fibrosis transmembrane conductance regulator 6–7
- Cytomegalovirus 231–2, 235, 476–7
 in children 489
- Cytosine arabinoside, pulmonary toxicity 407, 412–13
- Cytotoxic antibiotics, pulmonary toxicity 406–11
 bleomycin 406–10
 mitomycin C 410–11
- Dermatomyositis 27, 331–5
 chronic interstitial lung disease 333, 335
 clinical course and therapy 335
- Desquamative interstitial pneumonia 442–4
 clinical features 443
 physiologic testing 443
 radiographic findings 443, 444
 treatment and course 443–4
- Desquamative interstitial pneumonitis 490–2
- Dexfenfluramine, pulmonary toxicity 28
- Diagnosis 113–21
 bronchoalveolar lavage and transbronchial biopsy 118–19
 chest CT scan 116–18
 initial clinical assessment 115–16
 surgical lung biopsy 119–20
 techniques *see* Diagnostic techniques
see also individual disease states
- Diagnostic techniques 101–11
 bronchoalveolar lavage *see* Bronchoalveolar lavage
 fiberoptic bronchoscopy 102–3
 open lung biopsy 109–10
 percutaneous needle biopsy 107
 surgical biopsy 107–8
 transbronchial biopsy 103–4
 video-assisted thoracoscopy 108–9
- Diffuse infiltrative lung disease
 gas exchange in 73–4
 intensive care 480–1
 pathology 12–35
- Diffuse interstitial pulmonary fibrosis 437–63
 Allergic bronchopulmonary mycosis 446
 Alveolar proteinosis 452–5
 clinical presentation 452–3
 laboratory testing 454
 physiologic testing 453
 radiographic appearance 453, 454
 treatment and outcome 454–5

- Churg-Strauss syndrome 446-7
- Desquamative interstitial pneumonia 442-4
 clinical features 443
 physiologic testing 443
 radiographic findings 443
 treatment and course 443-4
- Eosinophilic pneumonias 444-5
 radiographic features 447-8
- Histiocytosis X 437-9
 clinical findings 438
 diagnosis 438-9
 physiologic testing 438
 radiographic findings 438
 treatment and clinical course 439
- Idiopathic pulmonary fibrosis 448-52
 clinical presentation 449
 diagnosis 451
 pathogenesis 448-9
 physiologic testing 450-1
 radiologic features 449-50, 451
 treatment 451-2
- Lymphangiomyomatosis 439-42
 clinical findings 440
 physiologic testing 440
 radiographic findings 440, 441
 treatment and course 440, 442
- Lymphocytic interstitial pneumonia 455-6
 clinical presentation 455
 diagnosis 456
 physiologic testing 456
 radiographic appearance 455, 456
 treatment and outcome 456
- Neurofibromatosis 442
- Tuberous sclerosis 442
- Diffuse panbronchiolitis 8
- Diffusing capacity 72
- Digital clubbing 47
- Dimethyl sulfate 160
 radiological findings 161
- Diphenylhydantoin, pulmonary toxicity 427-8
- Dipyridamole, pulmonary toxicity 426-7
- Dirofilaria immitis* 22
- Docetaxel, pulmonary toxicity 407, 415
- Drug-induced pulmonary disorders 403-36
 Anticonvulsants 427-8
 carbamazepine 428
 diphenylhydantoin 427-8
 Anti-inflammatory agents 415-19
 gold 419
 methotrexate 417
 non-steroidal anti-inflammatory drugs 416-17
 penicillamine 417-19
 salicylates 416
 Antimicrobial agents 419-21
 hypersensitivity lung disease 420
 isoniazid 421
 minocycline 421
 nitrofurantoin 420-1
 Cancer chemotherapy agents 406-15
 alkylating agents 411-12
 antimetabolites 412-13
 cytotoxic antibiotics 406-11
 nitrosoureas 413-14
 Cardiac agents 422-7
 angiotensin-converting enzyme inhibitors 426
 antiarrhythmic drugs 422-6
 beta-adrenergic receptor blocking agents 426
 dipyridamole 426-7
 hydralazine 427
 protamine 427
 Clinical syndromes 404-6
 alveolar hypoventilation 406
 bronchiolitis obliterans 405
 bronchospasm 405
 hypersensitivity lung disease 404
 non-cardiogenic pulmonary edema 404-5
 pneumonitis/fibrosis 404
 pulmonary-renal syndrome 405
 systemic lupus erythematosus 405
 Diffuse lung disease 27-8
 bronchoalveolar lavage 56
 Illicit drug use 428-30
 cocaine 429
 foreign body granulomatosis 429-30
 opiates 429
 tocolytic therapy 428
 Drug toxicity 239, 241
see also Drug-induced pulmonary disorders
- Emphysema
 centriacinar 11
 panacinar 11
 pathology 10-11
 pulmonary function tests 75
see also Chronic obstructive pulmonary disease
- Enterobacter* spp. 130, 229, 282
- Environmental lung disorders 141-84
 Inhalation of toxic gases/fumes 158-77
 lipid-soluble agents 160-1
 metal vapors and aerosols 167-9
 organophosphates 169-70
 smoke and carbon monoxide 170-7
 treatment 177
 water-soluble agents 161-7
 Mineral pneumoconiosis 148-58
 asbestosis 152-8
 coal 148-50
 silica 151-2
 Organic pneumoconiosis 141-8
 bagassosis 146
 bird fancier's disease 145
 byssinosis 146
 clinical presentations 142-3
 farmer's lung 144, 145
 food production alveolitis 147
 humidifier fever 146-7
 pathology 141-2
 radiological appearance 143-4
 suberosis 147-8
 treatment 148
- Eosinophilia
 BAL markers 58
see also Eosinophilic lung disease; Eosinophilic pneumonias
- Eosinophilic lung disease 21-3
- Eosinophilic pneumonias 444-5
 acute 445
 intensive care 445, 480
 chronic 445
 idiopathic hypereosinophilic syndrome 445
 radiographic findings 447-8
- Epithelial lesions 34-5
- Epithelioid hemangioendothelioma 34
- Epstein-Barr virus 131
 in children 489
- Escherichia coli* 130, 228, 229, 282

- Ethchlorvynol, pulmonary toxicity 28
 Examination *see* History and examination
 Expiratory reserve volume 65
 Extrinsic allergic alveolitis
 bagassosis 146
 bird fancier's disease 145
 byssinosis 146
 farmer's lung 144, 145
 food production alveolitis 147
 humidifier fever 146-7
 suberosis 147-8
 treatment 148
- Farmer's lung 144, 145
 Fat embolism 56
 Fiberoptic bronchoscopy 102-3
 asthma 189-90
 chronic obstructive pulmonary disease 197
 cystic fibrosis 214
 Fibrosing alveolitis 490-2
 Fibrosing pleurisy 156
 Flecainide, pulmonary toxicity 425
 Flexible fiberoptic bronchoscopy
 asthma 189-90
 chronic obstructive pulmonary disease 197
 cystic fibrosis 214
 Fluid balance 245-6
 Food production alveolitis 147
 Forced expiratory flow 66
 Forced expiratory volume 66
 Foreign body granulomatosis 429-30
 Fotemustine, pulmonary toxicity 407, 414
 Functional residual capacity 65
 Fungal infections 133-5, 476
 in immunodeficiency 229, 231, 232
 aspergillus 229, 231-2
 Candida albicans 229, 233
 Cryptococcus neoformans 231
 Histoplasma capsulatum 229, 231
 leukemia and lymphoma 284
- Gaucher's disease 300-2
 clinical presentation 301
 physiologic findings 301-2
 treatment 302
 Gold salts, pulmonary toxicity 28, 419
 Goodpasture's syndrome 23, 359-61, 362
 Granulomatosis *see* Pulmonary angitis and granulomatosis
 Granulomatous reactions 18-21
 hypersensitivity pneumonia 19
 necrotizing granulomatosis and vasculitis 19-21
 sarcoidosis 18-19
 Ground-glass opacity 117, 236
 sarcoidosis 307-11
- Haloperidol, pulmonary toxicity 28
 Hamman Rich syndrome 14, 481
 Heart, in sickle cell disease 269
 Hematological disorders 263-94
 Hemophilia 271-2
 Leukemia 281-7
 infectious complications 283-5
 non-infectious complications 285-7
 pleural disease 281-2
 pulmonary parenchymal involvement 282
 radiographic features 281
- Lymphoma 272-81
 Hodgkin's disease 273
 non-Hodgkin's lymphoma 273-7
 primary lymphoid lung lesions 277-81
 radiographic features 273-7
 Sickle cell disease 263-71
 acute chest syndrome 264-8
 hypoxemia 271
 imaging 269-70
 lung function 270-1
 pulmonary hypertension 268-9
 respiratory system in 264
 Hemophilia 271-2
Hemophilus influenzae 130, 213, 282, 469
 Hemoptysis 45
 Hemorrhage
 alveolar
 bronchoalveolar lavage 56
 systemic lupus erythematosus 341-2
 pulmonary *see* Pulmonary hemorrhage
 Henoch-Schönlein purpura 23
 Hermansky-Pudlack syndrome 302
 Herpes virus 233, 236
 Hexamethonium, pulmonary toxicity 28
 Histiocytosis
 in children 492, 493
 see also Histiocytosis X
 Histiocytosis X 437-9
 bronchoalveolar lavage 56
 clinical findings 438
 diagnosis 438-9
 physiologic testing 438
 radiographic findings 438, 439
 treatment and clinical course 439
Histoplasma capsulatum 54, 133, 229, 231
 History and examination 45-9
 diffuse radiological shadowing 48-9
 respiratory examination 47-8
 auscultation 48
 inspection 47
 palpation 47
 percussion 48
 sputum 48
 respiratory history 45-7
 Hodgkin's disease 273
 radiographic findings 273-7
 Honeycomb lung 487, 492, 493
 Human immunodeficiency virus 473-7
 bacterial pneumonia 473-4
 and bronchiectasis 205
 cytomegalovirus 476-7
 fungal disease 476
 mycobacterial disease 476
 Pneumocystis carinii pneumonia 474-6
 see also Immunodeficiency
 Humidifier fever 146-7
 Hydralazine, pulmonary toxicity 427
 Hydrogen sulfide, pulmonary toxicity 161, 163
 exposed population 163
 mechanism of lung injury 163
 radiological findings 166
 Hypereosinophilic syndrome 22
 Hypersensitivity lung disease 404
 antibiotic-induced 420
 see also Hypersensitivity pneumonia
 Hypersensitivity pneumonia 19, 20
 bronchoalveolar lavage 56
 Hypocalcemia, hypocalcemia and interstitial lung disease 302
 Hypoxemia, in sickle cell disease 271

- Idiopathic hypereosinophilic syndrome 445
- Idiopathic pulmonary fibrosis 448–52
 bronchioalveolar lavage 56
 clinical presentation 449
 diagnosis 451
 pathogenesis 448–9
 physiologic testing 450–1
 radiologic features 449–50, 451
 serum markers 51
 treatment 451–2
- Idiopathic pulmonary hemosiderosis 361, 363–6
- Idiopathic rapidly progressive glomerulonephritis 365–8
- Ifosfamide, pulmonary toxicity 407, 412
- Illicit drug use, pulmonary toxicity 428–30
 cocaine 429
 foreign body granulomatosis 429–30
 opiates 429
- ILO classifications 83–4
- Immunodeficiency 227–44, 473–9
 bone marrow transplant recipients 477–9
 HIV 473–7
 bacterial pneumonia 473–4
 cytomegalovirus 476–7
 fungal disease 476
 mycobacterial disease 476
pneumocystis carinii pneumonia 474–6
- infections 229–37
 bacterial 229
 fungal 229–31
 mycobacterial 237, 238–9
Pneumocystis carinii 233, 236–7
 septic emboli 231
 viral infections 231–3, 234, 235
- non-infectious diseases 237–43
 drug toxicity 239, 241
 lymphocytic-interstitial pneumonia 241, 243
 neoplasms 237, 239, 240
 non-specific interstitial pneumonia 243
 pulmonary edema 239
- Infection 125–39
 atypical mycobacteria 137–8
 bacterial pneumonias and mycoplasmal pneumonia 126–30
 causing diffuse pulmonary disease 125
 chronic necrotizing pulmonary aspergillosis 138–9
 necrotizing pulmonary 372
 pneumonias due to parasites 135–6
 presenting as diffuse pulmonary disease 125–6
 chronic infections 136–7
 tuberculosis and fungal infections 131–5
 viral pneumonias 130
- Influenza virus 130–1, 213, 282, 469
- Inspiratory capacity 66
- Inspiratory reserve volume 65
- Intensive care 465–86
 imaging 465–8
 CT scanning 467–8
 portable chest radiograph 465–7
- immunocompromised host 473–9
 bone marrow transplant recipients 477–9
 HIV 473–7
- metastatic cancer 481–2
- non-infectious diffuse lung disease 480–1
- specific disease states 468–73
 aspiration 471–3
 pneumonia 468–71
- Interleukin-2, pulmonary toxicity 407, 414
- Interstitial lung disease
 bronchoalveolar lavage 57–8
 in children 487–98
 alveolar proteinosis 494, 495
 auto-immune lung disease 492
 chronic pulmonary fibrosis due to recurrent aspiration 496–7
 fibrosing alveolitis/desquamative interstitial pneumonitis 490–2
 histiocytosis 492
 lymphangiomas 494, 496
 lymphoid interstitial pneumonitis 489–90
Pneumocystis carinii pneumonia 488–9
 pulmonary hemosiderosis 493–4, 495
 sarcoidosis 492–3
 viral pneumonia 489
- chronic *see* Chronic interstitial lung disease
- hypocalciuria, hypocalcemia and 302
- pulmonary function tests 76
- Intrathoracic lymphadenopathy 273–4
- Isoniazid, pulmonary toxicity 421
- Klebsiella* spp. 130, 205, 229, 282
Klebsiella pneumoniae 228
- Langerhans' cell granulomatosis 32–3
- Legionella* spp. 54, 469
Legionella pneumophila 129, 283
- Leukemia 281–7
 infectious complications 282–5
 bacteria 282–3
 fungi 284
 mycobacteria 283–4
Pneumocystis carinii 284
 viruses 284–5
- non-infectious pulmonary complications 285–7
 chemotherapy-induced 285–6
 pulmonary hemorrhage 286–7
 radiation-induced 285
- pleural disease 281–2
- pulmonary parenchymal involvement 282
- radiographic features 281
- Lipid-soluble toxic agents 160–1
- Loeffler's syndrome 22
- Lomustine, pulmonary toxicity 407, 414
- Lung cancer *see* Bronchioalveolar carcinoma; Tumors
- Lung capacities 65–6
- Lung function tests *see* Pulmonary function tests
- Lung mechanics 74–5
 elastic recoil, static pressure-volume relationship 74–5
 respiratory muscle function 74
- Lung transplantation 201
- Lung volume reduction surgery 201–2
- Lung volumes 65–6, 68–9
 multibreath helium equilibration method 68–9
 multibreath nitrogen wash-out method 69
 plethysmography 69
 sickle cell disease 270–1
 single breath helium dilution method 69
 single breath nitrogen method 69
- Lymphangioleiomyomatosis 33, 439–42
 clinical findings 440
 physiologic testing 440
 radiographic findings 440, 441
 treatment and course 440, 442
- Lymphangiomas 494, 496
- Lymphangitic carcinomatosis 389–99
 clinical manifestation 390–1
 definite diagnosis 391–4
 pathology 390

- Lymphangitic carcinomatosis *continued*
 radiologic diagnosis 394–9
 chest radiograph 395
 computed tomography 395–7
 differential diagnosis 397–9
 radionuclide study 397
 treatment 399
- Lymphocytic interstitial pneumonia 241–3, 455–6
 clinical presentation 455
 diagnosis 456
 physiologic testing 456
 radiographic appearance 455, 456
 treatment and outcome 456
- Lymphocytosis 58
- Lymphoid interstitial pneumonia 280
 in children 489–90
- Lymphoma 272–81
 Hodgkin's disease 273
 infectious complications 282–5
 bacteria 282–3
 fungi 284
 mycobacteria 283–4
Pneumocystis carinii 284
 viruses 284–5
 lymphoid lung lesions 277–81
 angioimmunoblastic lymphadenopathy 280
 Castleman's disease 281
 lymphoid interstitial pneumonia 280
 lymphomatoid granulomatosis 280–1
 post-transplantation lymphoproliferative disorder 278–80
 primary pulmonary lymphoma 277–8
 non-Hodgkin's lymphoma 273
 non-infectious pulmonary complications 285–7
 chemotherapy-induced 285–6
 pulmonary hemorrhage 286–7
 radiation-induced 285
 radiographic features 273–7
- Lymphomatoid granulomatosis 280–1, 317–19
 diagnosis 317–18
 biopsy 318
 chest radiograph and computed tomography 317, 318
 laboratory findings 317–18
 treatment 319
- Lymphoproliferative lesions 33–4
- Magnetic resonance imaging 92–4
- Malignant mesothelioma 156
- Maximal voluntary ventilation 66
- Measles pneumonia 131
- Melphalan, pulmonary toxicity 407, 411
- Metabolic disease 295–304
 amyloidosis 295–7
 Gaucher's disease 300–2
 Hermansky-Pudlack syndrome 302
 hypocalcemia, hypocalcemia and interstitial lung disease 302
 metastatic pulmonary calcification 297–8
 Niemann-Pick disease 302
 pulmonary alveolar microlithiasis 298–300
 uremia 295
- Metal vapors and aerosols 167–9
- Metastatic lung tumors 35, 481–2
- Metastatic pulmonary calcification 297–8
- Methotrexate, pulmonary toxicity 28, 407, 412, 417
- Mexilitine, pulmonary toxicity 426
- Mineral pneumoconiosis 148–58
 Asbestosis 152–8
 fibrosing pleurisy 156
 lung cancer 156–7
 malignant mesothelioma 156
 pleural thickening 155–6
 pulmonary fibrosis 153–5
- Coal 148–50
 clinical presentation 149
 management and prevention 150
 radiological features 149–50
- Silica 150–2
 management and prevention 152
 radiological features 152
- Minocycline, pulmonary toxicity 28, 421
- Mitomycin C, pulmonary toxicity 407, 410–11
- Mitral stenosis 370–2
- Mixed connective tissue disease 342–3
- Mucolytics 200
- Mucorales* spp. 284
- Mucor* spp. 228
- Multibreath helium equilibration method 68–9
- Multibreath nitrogen wash-out method 69
- Mycobacterial infection 237, 238–9, 476
 leukemia and lymphoma 283–4
- Mycobacterium* spp. 35
Mycobacterium avium-intracellulare 137, 237, 417
Mycobacterium kansasii 137, 237
Mycobacterium tuberculosis 237, 238–9, 283
- Mycoplasma pneumoniae 126–30
Mycoplasma pneumoniae 54, 127–8, 283, 469
- Necrotizing granulomatosis 19–21
- Necrotizing pulmonary infections 372
- Neurofibromatosis 442
- Neutrophilia, BAL markers in 58
- Nickel carbonyl 167
 mechanism of lung injury 168
 radiological findings 169
- Nitrofurantoin, pulmonary toxicity 28, 420–1
- Nitrogen oxides, pulmonary toxicity 160
 clinical symptoms 161
 exposed population 160
 mechanism of lung injury 160
 radiological findings 161
- Nitrosoureas, pulmonary toxicity 407, 413–14
 carmustine 413–14
 chlorozotocin 414
 fotemustine 414
 lomustine 414
 semustine 414
- Nocardia* spp. 35, 283
- Non-cardiogenic pulmonary edema 404–5
- Non-granulomatous inflammation 12–17
 acute lung injury 12–14
 chronic patterns of reaction 15–17
 organizing pneumonia 14–15
- Non-Hodgkin's lymphoma 273
 radiographic features 273–7
- Non-steroidal anti-inflammatory drugs, pulmonary toxicity 416–17
- Nosocomial pneumonia 130
 intensive care 470–1
- Obstructive pulmonary disease 185–225
 asthma *see* Asthma
 bronchiectasis 202–11
 cystic fibrosis 211–17
see also Chronic obstructive pulmonary disease
- Occupational asthma 190–1

- Open lung biopsy 109–10
 Opiates, pulmonary toxicity 429
 Organic pneumoconiosis 141–8
 bagassosis 146
 bird fancier's disease 145
 byssinosis 146
 clinical presentation 142–3
 farmer's lung 145
 food production alveolitis 147
 humidifier fever 146–7
 pathology 141–2
 radiological appearance 143–4
 suberosis 147–8
 treatment 148
 Organizing pneumonia 14–15
 Organophosphates 169–70
 Overlap syndrome 342–3
 Oxygen, supplemental 201
- Paclitaxel, pulmonary toxicity 407, 415
 Palpation 57
 Panacinar emphysema 11
 Parasitic pneumonia 135–6
 Partial liquid ventilation 256
 Pathology 3–42
 acinar region 8, 10
 alveolar proteinosis 24–5
 amyloidosis 25–6
 progressive systemic sclerosis 27
 pulmonary involvement in collagen-vascular disease 26
 rheumatoid arthritis 26
 systemic lupus erythematosus 27
 bronchioles
 disorders of bronchi 3–7
 asthma 4–5
 bronchiectasis 5–7
 chronic bronchitis 3
 drug-induced diffuse lung disease 27–8
 emphysema 10–11
 eosinophilic lung diseases 21–3
 granulomatous reactions 18–21
 hypersensitivity pneumonia 19
 necrotizing granulomatosis and vasculitis 19–21
 sarcoidosis 18–19
 non-granulomatous inflammation 12–17
 acute lung injury 12–14
 chronic patterns of reaction 15–17
 organizing pneumonia 14–15
 pneumoconiosis 29–32
 asbestosis 30–1
 berylliosis 31–2
 coal-worker's pneumoconiosis 29
 cobalt-induced lung disease 32
 silicosis 30
 polymyositis and dermatomyositis 27
 progressive systemic sclerosis 27
 proliferative lesions 32–5
 epithelial lesions 34–5
 epitheloid hemangioendothelioma 34
 Langerhans' cell granulomatosis 32–3
 lymphangioliomyomatosis 33
 lymphoproliferative lesions 33–4
 metastatic tumors 35
 pulmonary calcifications and ossification 25
 pulmonary hemorrhage 23–4
 pulmonary involvement in collagen-vascular disease 26
 radiation 29
 rheumatoid arthritis 26
 Sjögren's syndrome 27
 systemic lupus erythematosus 27
 Peak expiratory flow 66
 Penicillamine, pulmonary toxicity 28, 417–19
 Percussion 48
 Percutaneous needle biopsy 107
 Phosgene, pulmonary toxicity 160
 clinical symptoms 161
 complications and sequelae 161
 exposed population 160
 mechanism of lung injury 160
 radiological findings 161
 Pink puffers 195
 Plethysmography 69
 Pleural thickening 155–6
 Pneumococcal pneumonia 126
 Pneumoconiosis 29–32
 asbestosis 30–1
 berylliosis 31–2
 coal-worker's pneumoconiosis 29
 cobalt-induced lung disease 32
 silicosis 30
Pneumocystis carinii pneumonia 90, 135, 228, 474–6
 in children 488–9
 immunodeficiency 233, 236–7
 leukemia and lymphoma 284
 Pneumonia
 Aspergillus 229, 231–2
 aspiration 472–3
 bacterial 126–30, 473–4
 bronchiolitis obliterans organizing 405, 480
 bronchoalveolar lavage 56
 chronic eosinophilic 22
 community-acquired 126–30
 intensive care 468–70
 cytomegalovirus 476–7
 desquamative interstitial 442–4
 clinical features 443
 physiologic testing 443
 radiographic findings 443, 444
 treatment and course 443–4
 eosinophilic 444–5
 acute 445, 480
 chronic 445
 idiopathic hypereosinophilic syndrome 445
 radiographic findings 447–8
 hypersensitivity 19, 20
 bronchoalveolar lavage 56
 intensive care 469–71
 lymphocytic-interstitial 241–3
 lymphoid interstitial 280
 in children 489–90
 measles 131
 mycoplasmal 126–30
 nosocomial 130
 intensive care 470–1
 organizing 14–15
 parasitic 135–6
 pneumococcal 126
 Pneumocystis carinii see *Pneumocystis carinii* pneumonia
 staphylococcal 126–7
 varicella 131, 132
 viral 130–1
 in children 489
 radiography 81
 Pneumonitis/fibrosis
 acute interstitial 14, 481
 acute lupus 341
 chemical 471–2

- Pneumonitis/fibrosis *continued*
 drug-induced 404
see also Pulmonary fibrosis
- Polymyositis 27, 331–5
 chronic interstitial lung disease 333, 335
 clinical course and therapy 335
- Positive end-expiratory pressure 253
- Post-transplantation lymphoproliferative disorder 278, 280
- Primary pulmonary lymphoma 277–8
- Procainamide, pulmonary toxicity 425
- Procarbazine, pulmonary toxicity 407, 415
- Progressive systemic sclerosis 27, 327–31
 chronic interstitial lung disease 328–9
 clinical course and therapy 329–31
 pulmonary hypertension and CREST syndrome 331
- Propranolol, pulmonary toxicity 28
- Protamine, pulmonary toxicity 427
- Proteus* spp. 229
- Pseudomonas* spp. 7, 205, 229
- Pseudomonas aeruginosa* 130, 213, 228, 282
- Pseudomonas cepacia* 213
- Pseudomonas maltophilia* 213
- Pulmonary alveolar microlithiasis 298–300
 lung physiologic testing 299
 radiographic findings 299–300
 treatment 300
- Pulmonary alveolar proteinosis *see* Alveolar proteinosis
- Pulmonary angitis and granulomatosis 305–24
 Churg-Strauss syndrome 319–21
 lymphomatoid granulomatosis 317–19
 sarcoidosis 305–13
 Wegener's granulomatosis 313–16
- Pulmonary calcifications 35
- Pulmonary edema 245–61
 clinical course and treatment 251–6
 diagnostic evaluation 249–51
 cardiogenic vs non-cardiogenic edema 249–50
 immunocompromised patients 239
 non-cardiogenic 404–5
 normal fluid balance 245–6
 pathophysiology and causes 246–9
 increased permeability 247–9
 intact endothelial barrier 246–7
 mixed causes 249
see also Adult respiratory distress syndrome
- Pulmonary fibrosis 153–5
 asbestosis 153–5
 aspiration-induced 496–7
 diffuse interstitial *see* Diffuse interstitial pulmonary fibrosis
 idiopathic *see* Idiopathic pulmonary fibrosis
 mitomycin C-induced 410
 and recurrent aspiration 496–7
see also Pneumonitis/fibrosis
- Pulmonary function tests 65–77
 abnormal ventilatory function 69–71
 airway hyperresponsiveness 71
 airway resistance 75
 amyloidosis 297
 asthma 76, 188
 chronic bronchitis 76
 chronic obstructive pulmonary disease 195–6
 cystic fibrosis 214
 disordered respiratory function 75–6
 asthma 75
 chronic bronchitis 75
 emphysema 75
 interstitial lung diseases 75
 emphysema 75
 expiratory flows 66
 interstitial lung disease 76
 lung mechanics 74–5
 lung volumes 65–7, 68–9
 multibreath helium equilibration method 68–9
 multibreath nitrogen wash-out method 69
 plethysmography 69
 single breath helium dilution method 69
 single breath nitrogen method 69
 pulmonary gas exchange 71–4
 alveolar-arterial oxygen pressure difference 73
 arterial blood gas analysis 73
 diffusing capacity 72
 resting and exercise gas exchange in diffuse lung disease 73–4
 response to inhaled bronchodilator 67–8
 sickle cell disease 270–1
 spirometry 66–7
 flow-volume loop 66–7
 standard 66
- Pulmonary gas exchange 71–4
 alveolar-arterial oxygen pressure difference 73
 arterial blood gas analysis 73
 diffuse lung disease 73–4
 diffusing capacity 72
- Pulmonary hemorrhage 23–4, 286–7, 357–76
 chemical and drug reactions 367–9
 coagulopathies 369–70
 Goodpasture's syndrome 359–61, 362
 idiopathic pulmonary hemosiderosis 361, 363–5
 idiopathic rapidly progressive glomerulonephritis 365–8
 intensive care 480
 mitomycin C-induced 410
 mitral stenosis 370–2
 necrotizing pulmonary infections 372
- Pulmonary hemosiderosis 493–4, 495
- Pulmonary hypertension
 mixed connective tissue disease 343
 progressive systemic sclerosis 331
- Pulmonary ossification 35
- Pulmonary-renal syndrome 405
see also Goodpasture's syndrome
- Q fever 129
- Quinidine, pulmonary toxicity 425
- Radiation, pulmonary toxicity 29, 285
- Radiological findings
 alveolar proteinosis 453
 amyloidosis 296–7
 asthma 190
 bronchiectasis 206–7
 bronchioalveolar carcinoma 380–8
 cavitation 387–8
 consolidation 381
 multifocal pattern 381–7
 pathology 380
 solitary presentation 380–1, 382
 carbon monoxide inhalation 175
 coal pneumoconiosis 149–50
 cystic fibrosis 214–16
 desquamative interstitial pneumonia 443, 444
 histiocytosis X 438, 439
 Hodgkin's disease 273–7
 idiopathic pulmonary fibrosis 449–50, 451
 inhalation of lipid-soluble agents 161

- inhalation of metal vapors/aerosols 169
 - inhalation of organophosphates 169–70
 - inhalation of water-soluble agents 164–6
 - leukemia 281
 - lymphangiomyomatosis 440, 441
 - lymphocytic interstitial pneumonia 455, 456
 - non-Hodgkin's lymphoma 273–7
 - pulmonary alveolar microlithiasis 299–300
 - sickle cell disease 269–70
 - silica pneumoconiosis 152
 - smoke inhalation 172–3
 - uremia 295, 296
 - Radiological investigations 79–99
 - computed tomography 85–92
 - conventional chest radiography 79–85
 - magnetic resonance imaging 92–4
 - organic pneumoconiosis 143–4
 - see also* Radiological findings
 - Radionuclide studies
 - chronic interstitial lung disease 326–7
 - lymphangitic carcinomatosis 397
 - Residual volume 65
 - Respiratory syncytial virus 130
 - Retinoic acid, pulmonary toxicity 407, 414–15
 - Rheumatoid arthritis 26, 335–9
 - bronchiectasis 339
 - chronic interstitial lung disease 335–9
 - clinical course and therapy 339
 - obliterative bronchiolitis 339
 - Riley-Day syndrome 487

 - Salicylates, pulmonary toxicity 28, 416
 - asthma 191
 - Sarcoidosis 305–13, 492–3, 494
 - bronchoalveolar lavage 56
 - diagnosis 305–13
 - biopsy 312–13
 - chest radiograph 305–6
 - computed tomography 306–11
 - pathology 18–19
 - treatment 313
 - Schistosomiasis 136
 - Semustine, pulmonary toxicity 407, 414
 - Septic emboli 231, 234
 - Serratia* spp. 229
 - Serratia marcescens* 130, 282
 - Serum markers 51–4
 - Sickle cell disease 263–71
 - acute chest syndrome 264–8
 - multi-organ failure 266–8
 - hypoxemia 271
 - imaging 269–70
 - lung function 270–1
 - pulmonary hypertension 268–9
 - respiratory system in 264
 - Silicosis 30, 150–2, 153
 - bronchoalveolar lavage 56
 - management and prevention 152
 - radiological features 152
 - Single breath helium dilution method 69
 - Single breath nitrogen method 69
 - Sjögren's syndrome 9, 27, 343–8
 - chronic interstitial lung disease 344–7
 - lymphoid pulmonary disorders 347–8
 - Smoke inhalation 170–3
 - carbon monoxide inhalation 173–5
 - chronic airflow obstruction 7
 - see also* Cigarette smoking
 - Sotalol, pulmonary toxicity 426
 - Spirometry 66–7
 - flow-volume loop 66–7
 - standard 66
 - Sputum
 - examination 48
 - production 45
 - Stannosis 158
 - Staphylococcal pneumonia 126–7
 - Staphylococcus aureus* 126–7, 205, 228, 469
 - Status asthmaticus 191–2
 - Streptococcus pneumoniae* 126, 282, 469
 - Streptococcus viridans* 228
 - Strongyloides* spp. 22
 - Suberosis 147–8
 - Sulfasalazine, pulmonary toxicity 28
 - Sulfur dioxide, pulmonary toxicity 161
 - exposed population 163
 - mechanism of lung injury 163
 - radiological findings 164, 166
 - Surgical biopsy 107–8, 119–20
 - Sweat chloride test 214
 - Systemic lupus erythematosus 27, 339–42
 - acute alveolar hemorrhage 341–2
 - acute lupus pneumonitis 341
 - chronic interstitial lung disease 340–1
 - drug-induced 405
 - intensive care 480

 - Theophylline 200
 - Tidal volume 65
 - Tocainide, pulmonary toxicity 425
 - Tocolytic therapy, pulmonary toxicity 428
 - Total lung capacity 65
 - Toxic gas/fume inhalation 158–77
 - carbon monoxide 173–5
 - lipid-soluble agents 160–1
 - clinical symptoms and signs 161
 - complications and sequelae 161
 - mechanism of lung injury 160
 - radiological findings 161
 - toxic agents 160
 - metal vapors and aerosols 167–9
 - mechanism of lung injury 168–9
 - radiological findings 169
 - toxic agents 167–8
 - organophosphates 169–70
 - smoke inhalation 170–3
 - smoking 175–7
 - treatment 177
 - water-soluble agents 161–7
 - clinical symptoms and signs 163–4
 - mechanism of lung injury 163
 - radiological findings 164–7
 - toxic agents 161–3
- Toxocara canis* 22
- Toxocariasis 135–6
- Toxoplasma gondii* 228
- Transbronchial biopsy 103–4, 118–19
- Tuberculosis 131, 133, 134, 136–7, 138
- Tuberous sclerosis 442
- Tumors 156–7
 - bronchoalveolar lavage 60
 - immunocompromised patients 237, 239, 240
 - metastatic 35, 481–2
 - see also* Bronchioalveolar carcinoma

- Uremia 295

- Varicella pneumonia 131, 132
- Vasodilators, inhaled 255-6
- Ventilation, mechanical 253-6
 - ventilator-induced lung damage 253-5
- Video-assisted thoracoscopy 108-9
- Viral infections 231-6
 - cytomegalovirus 231, 235
 - herpes virus 233, 236
 - leukemia and lymphoma 284-5
 - pneumonia 130-1, 489
- Viral pneumonia 130-1
 - in children 489
- Vital capacity 65

- Water-soluble toxic agents 161-7
- Wegener's granulomatosis 20, 21, 313-16
 - diagnosis 314-16
 - biopsy 315-16
 - bronchoscopic findings 314-15
 - chest radiograph 314, 315
 - computed tomography 314, 315
 - laboratory findings 315
 - treatment 316
- Wheeze 46
- Wucheria bancrofti* 22

- Zinc chloride 167
 - mechanism of lung injury 168-9
 - radiological findings 169